A single route to evaluate new diagnostic tests for COVID-19
CONDOR is accelerating how quickly promising COVID-19 diagnostics make it into real-world use. The platform is evaluating new COVID-19 diagnostics in the settings they will be used, such as in GP surgeries, care homes or hospitals, as well as their performance in laboratory settings. These tests will be used to support diagnosis and management of patients with suspected COVID-19, and collect data to help develop effective diagnostic pathways for subsequent waves of infection in the post-pandemic setting.
RE: FIVE LIFE SAVING DECTECTORS FROM BRAVEHEART 100% OWNED SUB COMPANY PARAYTEC17 Jun 2021 22:55
googled it, reach is basically a press release as opposed to regulatory RNS....so my timing question stands - why make an important and positive 'press' release regarding positive data around the Alzhiemers test on a Monday morning at 9:40 with no quotes from TB or others about the 'potential' of the test.
Marmited has shown that TB can take millions of shares here and would it be in his interest to take them on the cheap by dumbing down 'press'
RE: FIVE LIFE SAVING DECTECTORS FROM BRAVEHEART 100% OWNED SUB COMPANY PARAYTEC17 Jun 2021 22:40
What is a 'reach' announcement by the way? Surely any price sensitive announcement has to come from brh as the owners. If brh made a 7am rns about the positive progress with the alzhiemers test, there would have been more of an impact.
For 'reach' to step in and make an untimely announcement on our behalf sounds odd. I've never seen this before